Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotinib vs gefitinib in untreated EGFR-mutant advanced NSCLC
CTR20182129Phase 3Active
- Sponsor
- ACEA Pharmaceuticals
- Start
- Apr 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of icotinib in non-small cell lung cancer (NSCLC), sponsored by ACEA Pharmaceuticals. Started Apr 2019; status: active.
02
Drugs
icotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20182129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20182129.